Form 4: Neurocrine Biosciences Director Acquires Restricted Stock Units

Director George J. Morrow acquired 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences Inc. on May 22, 2024, which will vest on May 22, 2025.

Summary

• On May 22, 2024, George J. Morrow, a director of Neurocrine Biosciences Inc., acquired 2,869 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Neurocrine Biosciences' common stock upon vesting.
• The RSUs will vest in full on May 22, 2025.
• Following the transaction, Mr. Morrow directly owns 2,869 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of shares by a director is generally viewed as a positive sign, but it's a small transaction.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of RSUs by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates